Treatment of the patient with lung metastases

Current Problems in Surgery

Volumn 33, Issue 11, 1996, Pages 881-952

  Roth, Jack A ^a   Beech, Derrick J ^a   Pollock, Raphael E ^a   Fidler, Isaiah J ^a   Putnam Jr , Joe B ^a   Patel, Shreyaskumar R ^a   Benjamin, Robert S ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH PROMOTOR;

ANIMAL; CELL SURVIVAL; GENETICS; HUMAN; LUNG; LUNG RESECTION; LUNG TUMOR; METASTASIS; PATHOLOGY; PHYSIOLOGY; REVIEW; SARCOMA; SURVIVAL; TUMOR SUPPRESSOR GENE; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; GENES, TUMOR SUPPRESSOR; GROWTH SUBSTANCES; HUMANS; LUNG; LUNG NEOPLASMS; PNEUMONECTOMY; SARCOMA; SURVIVAL ANALYSIS;

EID: 0030294287     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-3840(96)80003-7     Document Type: Article

References (330)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1:571-3.
2. Fidler U. Special lecture: critical factors in the biology of human cancer metastasis: twenty-eight GHA clowes memorial award lecture. Cancer Res 1990;50:6130-8.
3. Fidler U, Kripke ML. Metastasis results form pre-existing variant cells within a malignant tumor. Science 1977;197:893-5.
4. Sreekantaiah C, Ladanyi M, Rodriguez E, Chaganti R. Chromosomal aberrations in soft tissue tumors. Am J Pathol 1994;! 11:121-34.
5. Mrozek K, Karakousis C, Bloomfield C. Chromosome 12 breakpoints are cytogenetically different in benign and malignant lipogenic tumors: localization of breakpoints in lipoma to 12ql5 and in myxoid liposarcoma to 12ql3.3. Cancer Res 1993:53:1670-5.
6. Shipley J, Crew J, Gusterson B. The molecular biology of soft tissue sarcoma. Eur J Cancer 1993;29A:2054-8.
7. Knight J. The molecular genetics of soft tissue sarcoma. Eur J Cancer 1990:26:511-3.
8. Knight J, Renwick P, Cin P, Van Den Berghe H, Fletcher C. Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res 1995;55:24-7.
9. Waterfield M. Platelet-derived growth factor is structurally related to the putative transforming protein P28SIS of simian sarcoma virus. Nature 1983;304:35-9.
10. Shin D, Gupta V, Donner L, et al. Aberrant oncogene expression in uncultured human sarcoma and melanoma. Anticancer Res 1987;7:1117-24.
11. Barrios C, Castresana JS, Ruiz J, Kreicberg SA. Amplification of the c-myc proto-oncogene in soft tissues sarcomas. Oncology 1994;51:13-7.
12. Taparowsky E, Shimizu K, Goldfarb M, Wigler M. Structure and activation of the human N-ras gene. Cell 1983;34:581-6.
13. Kundra V, Anand-Apte B, Feig L, Zetter B. The chemotactic response to PDGF-BB: Evidence of a role for ras. J Cell Biol 1995; 130:725-31.
14. lyer A, Kmiecik TE, Park M, Daar 1. Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differ 1990;l:87-95.
15. Rong S, Donehower LA, Hansen MF, et al. Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res 1995;55:1963-70.
16. Nicolson GL. Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochim Biophys Acta 1988;948:175-224.
17. Cavanaugh PG, Nicolson GL. Purification and some properties of a lung-derived growth factor that differentially stimulates the growth of tumor cells metastatic to the lung. Cancer Res 1989;49:3928-33.
18. Van de Geer P, HunterT, Linberg R. Receptor protein tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994; 10:251-337.
19. Aaronson SA. Growth factors and cancer. Science 1992;254:1146-53.
20. Baserga R. Oncogenes and the strategy of growth factors. Cell 1994:79:927-30.
21. Heldin C, Westermark B. Platelet-derived growth factor: three isoforms and two receptor types. Trends Genet 1989:5:108-11.
22. Mori S, Takafumi U, Kuratsu S, Hosono N, Izawa K, Uchida A. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 1995:61:148-52.
23. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992:52:6194-9.
24. 23a. Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS, Yamamuro T. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 1993:68:1134-9.
25. Latres E, Drobnjak M, Pollack D, et al. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcoma. Am J Pathol 1994:145:345-55.
26. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-9.
27. Taubert H, Wurl P, Meye A, et al. Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma: identification of seven new mutations for soft tissue sarcomas. Cancer 1995;76:1187-96.
28. Cance WG, Brennan MF, Dudas ME, Huang C, Cordon-Cardo C. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 1990:323:1457-62.
29. 27a. Pollock RE, Lang A, Luo J, El-Naggar AK, Yu D. Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells. Oncogene 1996; 12:2035-9.
30. 27b.Wunder JS, Czitrom AA, Kandel R, Andrulis IL. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sacomas. J Natl Cancer Inst 1991;83:194-200.
31. Fidler U, Balch CM. The biology of cancer metastasis and implications for therapy. Curr Probl Surg 1987;24:137-209.
32. Poste G, Fidler U. The pathogenesis of cancer metastasis. Nature 1979;283:139-46.
33. Fidler U. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978;38:2651-60.
34. Fidler IJ, Poste G. The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. Semin Oncol 1985;12:207-21.
35. Nicolson GL. Generation of phenotypic diversity and progression in metastatic tumor cells. Cancer Metastasis Rev 1984;3:25-42.
36. HeppnerG. Tumor heterogeneity. Cancer Res 1984;44:2259-65.
37. Aukerman SL, Fidler IJ. The heterogeneous nature of metastatic neoplasms: relevance to biotherapy. In: Oldham RK, editor. Principles of cancer biotherapy. 2nd ed. New York: Marcel Dekker, 1991:23-53.
38. Willis RA. The spread of tumors in the human body. 3rd ed. London: Butterworth & Co. Ltd., 1973:1-417.
39. Sugarbaker EV. Cancer metastasis: a product of tumor-host interactions. Curr Probl Cancer 1979;3:1-59.
40. Hart IR, Goode NT, Wilson RE. Molecular aspects of the metastatic cascade. Biochim BiophysActa 1989;989:65-84.
41. Liotta LA, Steeg PS, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
42. Weiss L. Principles of metastasis. Orlando: Academic Press, 1985:1-425.
43. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? GHA Clowes Memorial Award Lecture. Cancer Res 1986;46:467-73.
44. Folkman J, Klagsburn M. Angiogenic factors. Science 1987;235:444-7.
45. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991 ;324:1-8.
46. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992:84:1875-987.
47. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990;348:555-7.
48. Gabbert H. Mechanisms of tumor invasion: evidence from in vivo observations. Cancer Metastasis Rev 1985;4:283-310.
49. Strauli P, Haemmerli O. The role of cancer cell motility in invasion. Cancer Metastasis Rev 1984:3:127-43.
50. Volk T, Geiger B, Raz A. Motility and adhesive properties of high and low metastatic murine neoplastic cells. Cancer Res 1984;44:811-24.
51. Doyle GM, Sharief Y, Mohler JL. Prediction of metastatic potential by cancer cell motility in the Dunning R-3327 prostatic adenocarcinoma in vivo model. J Urol 1992:147:514-8.
52. Behrens J, Mareel MM, Van Ray FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989;108:2435-47.
53. Liotta LA, Mandler R, Murano G, et al. Tumor cell autocrine motility factor. Proc Natl Acad Sei U S A 1986;83:3302-6.
54. Silletti S, Watanabe H, Hogan V, Nabil R, Raz A. Purification of B16-F1 melanoma autocrine motility factor and its receptor. Cancer Res 1991 ;51:3301-11.
55. Watanabe H, Carmi P, Hogan V, et al. Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. J Biol Chem 1991;266:13442-8.
56. LotanR,Amos B, Watanabe H, Raz A. Suppression of motility factor receptor expression by retinoic acid. Cancer Res 1992;52:4878-84.
57. Watanabe H, Shinozaki T, Raz A, Chigira M. Expression of autocrine motility factor receptor in serum- and protein-independent fibrosarcoma cells: implications for autonomy in tumor-cell motility and metastasis. Int J Cancer 1993;53:689-96.
58. Giordano S, Zhen Z, Medico E, Gaudino G, Galimi F, Comoglio PM. Transfer of mitogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. Proc Natl Acad Sei U S A 1993;90:649-53.
59. Yabkowitz R, Mansfield PJ, Dixit VM, Suchard SJ. Motility of human carcinoma cells in response to thrombospondin: relationship to metastatic potential and thrombospodin structural domains. Cancer Res 1993;53:378-87.
60. Ruoslahti E. Control of cell motility and tumour invasion by extracellular matrix interactions: The Walter Herbert Lecture. Br J Cancer 1992;66:239-42.
61. Jiang WG, Puntis MCA, Hallett MB. Monocyte-conditioned media possess a novel factor which increases motility of cancer cells. Int J Cancer 1993 ;53:426-31.
62. Liotta LA, Stracke ML, Aznavoorian SA, Beckner ME, Schiffman E. Tumor cell motility. Semin Cancer Biol 1991;2:111 -5.
63. Nabi IR, Watanabe H, Raz A. Autocrine motility factor and its receptor: role in cell locomotion and metastasis. Cancer Metastasis Rev 1992;11:5-21.
64. Woolley DE. Collagenolytic mechanisms in tumor cell invasion. Cancer Metastasis Rev 1984;3:361-72.
65. Liotta LA. Tumor invasion and metastasis: role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 1986;46:1-7.
66. Nakajima M, Chop AM. Tumor invasion and extracellular matrix degradative enzymes: regulation of activity by organ factors. Semin Cancer Biol 1991;2:115-29.
67. Terranova VP, Hujanen ES, Martin GR. Basement membrane and the invasive activity of metastatic tumor cells. J Natl Cancer Inst 1986;77:311-6.
68. Sloane BE, Honn KV. Cysteine proteinase and metastasis. Cancer Metastasis Rev 1984:3:249-65.
69. Stearns ME, Wang M. Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res 1993;53:878-83.
70. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992; 10:145-52.
71. Johnson MD, Torn JA, Lippman ME, Dickson RB. The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 1993;53:873-9.
72. Fisher ER, Fisher B. Recent observations on concepts of metastasis. Arch Pathol Lab Med 1967;83:321-4.
73. Fisher B, Fisher ER. The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet 1966; 122:791-7.
74. del Regato JA. Pathways of metastatic spread of malignant tumors. Semin Oncol 1977:4:33-8.
75. Fisher B, Fisher ER. The organ distribution of disseminated 5lCr-labeled tumor cells. Cancer Res 1967:27:412-9.
76. Carr I. Lymphatic metastasis. Cancer Metastasis Rev 1983;22:307-19.
77. Fisher B, Fisher ER. Studies concerning the regional lymph node in cancer. Cancer 1971:27:1001-9.
78. Fisher B, Fisher ER. Barrier function of lymph node to tumor cells and erythrocytes: 1. Normal nodes. Cancer 1967:20:1907-18.
79. Zeidman I, Buss JM. Experimental studies on the spread of cancer in the lymphatic system: I. Effectiveness of the lymph node as a barrier to the passage of embolie tumor cells. Cancer Res 1954; 14:403-10.
80. Balch CM, Cascinelli N, Milton GW, Sim FH. Surgical decisions regarding lymph node dissection for stage I melanoma patients: pros and cons of immediate vs. delayed lymphadenectomy. In: Balch CM, Milton GW, editors. Cutaneous melanoma: clinical management and treatment results worldwide. Philadelphia: JB Lippincott, 1985:111-42.
81. Fidler U. Quantitative analysis of distribution and fate of tumor emboli labeled with l25I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst 1970:45:773-82.
82. Glaves D. Correlation between circulating cancer cells and incidence of métastases. Br J Cancer 1983;48:665-70.
83. Weiss L. Metastatic inefficiency: causes and consequences. Cancer Metastasis Rev 1986;3:l-24.
84. Fidler U. The relationship of embolie homogeneity, number, size and viability to the incidence of experimental metastasis. Eur J Cancer 1973;9:223-7.
85. Liotta LA, Kleinerman J, Saidel GM. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976;36:889-94.
86. Updyke TV, Nicolson GL. Malignant melanoma lines selective in vitro for increased homotypic adhesion properties have increased experimental metastatic potential. Clin Exp Metastasis 1986;4:231-8.
87. Gasic GJ. Role of plasma, platelets and endothelial cells in tumor metastasis. Cancer Metastasis Rev 1984;3:99-144.
88. Fidler U, Bucana CD. Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes. Cancer Res 1977;37:3945-56.
89. Nicolson GL. Cancer progression and growth: relationship of paracrine and automne growth mechanisms to organ preference of metastasis. Exp Cell Res 1993;204:171-80.
90. McCarthy JB, Skubitz APN, lida J, Mooradian DL, Wilke MS, Furcht LT. Tumor cell adhesive mechanisms and their relationship to metastasis. Semin Cancer Biol 1991;2:155-69.
91. Mareel M, Vleminckx K, Vermeulen S, et al. Homotypic cell-cell adhesion molecules and tumor invasion. In: Graumann J, Drukker J, editors. Progress in histo- and cytochemistry: histochemistry of receptors. Stuttgart: Fischer Verlag, 1992:102-6.
92. Yamamura K, Kibbey MC, Kleinman HK. Melanoma cells selected for adhesion to laminin peptides have different malignant properties. Cancer Res 1993;53:423-8.
93. MacNeil S, Wagner M, Wowk I, et al. Intracellular regulation of cell adhesion to extracellular matrix components in murine B16 melanoma cells. Melanoma Res 1992;2:345-54.
94. Taraboletti G, Belotti D, Giavazzi R, Sobel ME, Castronovo V. Enhancement of metastatic potential of murine and human melanoma cells by laminin receptor peptide G: attachment of cancer cells to subendothelial matrix as a pathway for hematogenous metastasis. J Natl Cancer Inst 1993:85:235-40.
95. Nakai M, Mundy GR, Williams PJ, Boyce B, Yoneda T. A synthetic antagonist to laminin inhibits the formation of osteolytic métastases by human melanoma cells in nude mice. Cancer Res 1992;52:5395-9.
96. Weinel RJ, Rosendahl A, Neumann K, et al. Expression and function of VLA-oc2, -OC3, -a5 and -oc6-integrin receptors in pancreatic carcinoma. Int J Cancer 1992;52:827-33.
97. Birch M, Mitchell S, Hart IR. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res 1991;51:6660-5.
98. MatsumuraY, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992;340:1053-8.
99. Sy MS, Guo YJ, Stamenkovic I. Inhibition of tumor growth in vivo with a soluble CD44~immunoglobulin fusion protein. J Exp Med 1992; 176:623-7.
100. Dvorak HF, Seneger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1983;2:41-75.
101. Warren BA. Origin and fate of blood-borne tumor emboli. Cancer Biol Rev 1981:2:95-122.
102. Clifton EE, Grossi CE. The rationale of anticoagulants in the treatment of cancer. J Med 1974;5:107-16.
103. Ewing J. Neoplastic diseases: a treatise on tumors. 3rd ed. Philadelphia: WB Saunders, 1928:1-1127.
104. Hujanen ES, Terranova VP. Migration of tumor cells to organ-derived chemoattractants. Cancer Res 1985:45:3517-21.
105. Pauli BU, Schwanz DE, Thonar EJM, Kuttner KE. Tumor invasion and host extracellular matrix. Cancer Metastasis Rev 1983:2:129-52.
106. Nicolson GL, Dulski KM. Organ specificity of metastatic tumor colonization is related to organ-selective growth properties of malignant cells. Int J Cancer 1986:38:289-94.
107. Horak E, Darling DL, Tarin D. Analysis of organ-specific effects on metastatic tumor formation by studies in vitro. J Natl Cancer Inst 1986:76:913-22.
108. Naito S, Giavazzi R, Fidler U. Correlation between the in vitro interaction of tumor cells with an organ environment and metastatic behavior in vivo. Invasion Metastasis 1987:7:16-29.
109. Price JE, Tarin D, Fidler U. The influence of organ microenvironment on pigmentation of a metastatic murine melanoma. Cancer Res 1988:48:2258-64.
110. Price JE, Naito S, Fidler U. The role of the organ microenvironment in the selective process of metastasis. Clin Exp Metastasis 1988:6:91-102.
111. Failkow PJ. Clonal origin of human tumors. Annu Rev Med 1979:30:135-9.
112. Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science 1987:238:193-7.
113. Muleris M, Salmon RJ, Dutrillaux B. Chromosomal study demonstrating the clonal evolution and metastatic origin of a metachronous colorectal carcinoma. Int J Cancer 1986:38:167-72.
114. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, et al. Allelotype of colorectal carcinomas. Science 1989;224:207-11.
115. Foulds L. The experimental study of tumor progression (a review). Cancer Res 1954;14:327-39.
116. Nowell PC. The clonal evolution of tumor cell populations. Science 1976:194:23-8.
117. Hart IR, Easty D. Tumor cell progression and differentiation in metastasis. Semin Cancer Biol 1991;2:87-97.
118. PagetS. Secondary growths of cancer of breast. Lancet 1989:1:571-3.
119. Luria SE, Delbruck M. Mutations of bacteria from virus sensitive to virus resistance. Genetics 1943:28:491-511.
120. Kripke ML. Speculation on the role of ultraviolet radiation in the development of malignant melanoma. J Natl Cancer Inst 1979:63:541-5.
121. Fidler U, Gruys E, Cifone MA, Barnes Z, Bucana C. Demonstration of multiple phenotypic diversity in a murine melanoma of recent origin. J Natl Cancer Inst 1981:67:947-55.
122. Aukerman SL, Price JE, Fidler U. Different deficiencies in the prevention of tumorigenic-low-metastatic murine K-1735 melanoma cells from producing métastases. J Natl Cancer Inst 1986:77:915-24.
123. Fidler I. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 1986:5:24-49.
124. Fidler IJ. Selection of successive tumor lines for metastasis. Nature 1973:242:148-9.
125. Talmadge JE, Fidler IJ. Cancer metastasis is selective or random depending on the parent tumor population. Nature 1982:27:593-4.
126. Talmadge JE, Fidler IJ. Enhanced metastatic potential of tumor cells harvested from spontaneous métastases of heterogeneous murine tumors. J Natl Cancer Inst 1982:69:975-80.
127. Talmadge JE, Wolman SR, Fidler IJ. Evidence for the clonal origin of spontaneous metastasis. Science 1982;217:361-3.
128. Fidler IJ, Talmadge JE. Evidence that intravenously derived murine pulmonary melanoma métastases can originate from the expansion of a single tumor cell. Cancer Res 1986:46:5167-71.
129. Fidler 1J. Immunostimulation-inhibition of experimental cancer metastasis. Cancer Res 1974;34:491-8.
130. Dvorak HF. Thrombosis and cancer. Hum Pathol 1987;18:275-84.
131. Zacharski LR, Henderson WG, Rickles RF, et al. Rationale and experimental design for the VA cooperative study of anticoagulation (warfarin) in the treatment of cancer. Cancer 1979;44:732-41.
132. Gasic G, Gasic T, Steward CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sei U S A 1968:61:46-52.
133. Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastasis. Ann Intern Med 1981;95:636-41.
134. Honn KV, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent. Science 1981:212:1270-4.
135. Aggarwal KC, Parks RE. Forskolin: a potential antimetastatic agent. Int J Cancer 1983:32:801-4.
136. Connor JC, Bucana CD, Fidler U, Schroit AJ. Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes: quantitative assessment of outer leaflet lipid by prothrombinase complex formation. Proc Natl Acad Sci USA 1989:86:3184-8.
137. Van De Water L, Tracy PB, Aronson D, Mann KG, Dvorak HF. Tumor cell generation of thrombin via functional prothrombinase assembly. Cancer Res 1985:45:5521-5.
138. Karpatkin S, Smerling A, Pearlstein E. Plasma requirement for the aggregation of rabbit platelets by an aggregating material derived from SV40-transformed 3T3 fibroblasts. J Lab Clin Med 1980:96:994-1001.
139. Watanabe M, Okochi E, Sugimoto Y, Tsuruo T. Identification of a platelet aggregating factor of murine colon adenocarcinoma 26: Mr 44,000 membrane protein as determined by monoclonal antibodies. Cancer Res 1988:48:6411-6.
140. Watanabe M, Sugimoto Y, Tsuruo T. Expression of a Mr 44,000 glycoprotein associated with thrombin-independent platelet aggregation in high metastatic variants of murine B16 melanoma. Cancer Res 1990:50:6657-62.
141. Grignani G, Jamieson GA. Platelets in tumor metastasis: generation of adenosine diphosphate by tumor cells is specific but unrelated to metastatic potential. Blood 1988:71:844-9.
142. McCulloch P, George WD. Warfarin inhibition of metastasis: the role of anticoagulation. BrJSurg 1987:74:879-83.
143. Millar RC. KetchamAS. The effect of heparin and warfarin on primary and metastatic tumors. J Med 1974;5:23-31.
144. Esmon CT, Sadowski JA, Suttie JW. A new carboxylation reaction. J Biol Chem 1975:250:4744-8.
145. Gallop PM, Lian JB, Hauschka PV. Carboxylated calcium-binding proteins and vitamin K. N Engl 1 Med 1979:302:1460-6.
146. Esumi N, Fan D, Fidler U. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 1991:51:4549-56.
147. Markwardt F. The comeback of hirudin: an old-established anticoagulant agent. Folia Haematol Int Mag Klin Morphol Blutforsch 1988:115:10-23.
148. Sato H, Suzuki M. Deformability and viability of tumor cells by transcapillary passage with reference to organ affinity in metastasis in cancer. In: Weiss L, editor. Fundamental aspects of metastasis. North-Holland: Amsterdam, 1976:311-7.
149. Fidler U, Gersten DM, Kripke ML. Influence of immune status on the metastasis of three murine fibrosarcomas of different immunoaenicities. Cancer Res 1979:39:3816-21.
150. Hannu N. Fidler U. The role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst 1980:65:801-9.
151. Fidler U. Macrophage and metastasis: a biological approach to cancer therapy: presidential address. Cancer Res 1985:45:4714-26.
152. Nicolson GL. Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 1988;7:143-88.
153. Li L, Nicolson GL, Fidler U. Direct in vitro lysis of metastatic tumor cells by cytokine-activated murine vascular endothelial cells. Cancer Res 1991 ;51:245-54.
154. Li L, Kilbourn RG, Adams J, Fidler U. Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Res 1991 ;51:2531-5.
155. Stuehr DJ, Griffith OW. Mammalian nitric oxide synthase. In: Meister A, editor. Advances in enzymology and related areas of molecular biology. New York: Interscience, 1992:287-346.
156. Fidler U, Lieber S. Quantitative analysis of the mechanism of glucocorticoid enhancement of experimental métastases. Res Commun Chem Pathol Pharmacol 1972;4:605-13.
157. Radomski MW, Palmer RMJ, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A 1990;87:10043-7.
158. Xie K, Fidler U. Induction of apoptosis in transformed fibroblasts can be mediated via endogenous and exogenous nitric oxide. Proc Am Assoc Cancer Res 1993;34:95-5.
159. Dong Z, Staroselsky AH, Zi X, Xie K, Fidler U. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res 1994:54:789-93.
160. Weinlechner. Wiener Medizinische Wochenschrift 1882;20.
161. Weinlechner. Wiener Medizinische Wochenschrift 1892;32:590.
162. Kronlein RU. Ueber lungenchirirugie. Berliner Klinische Wochenschrift 1884;9:129-32.
163. Mannix EP Jr. Resection of multiple pulmonary métastases 14 years after amputation for osteochondrogenic sarcoma of tibia; apparent freedom from recurrence 2 years later. J Thorac Surg 1953:26:544-9.
164. Divis G. Ein beitrag zur operativen behandlung der lungengeschwultse. Acta Chir Scand 1927;62:329-9.
165. Torek F. Removal of metastatic carcinoma of the lung and mediastinum: suggestions as to technic. Arch Surg 1930:21:1416-21.
166. Barney JD, Churchill EJ. Adenocarcinoma of the kidney with metastasis to the lung cured by nephrectomy and lobectomy. J Urol 1939:42:269-76.
167. Alexander J, Haight C. Pulmonary resection for solitary metastatic sarcoma and carcinoma. Surg Gynecol Obstet 1947:85:129-46.
168. Martini N, Huvos AG, Mike V, Marcove RC, Beattie EJ. Multiple pulmonary resections in the treatment of osteogenic sarcoma. Ann Thorac Surg 1971:12:271-80.
169. Rusch VW. Pulmonary metastasectomy: current indications (review). Chest 1995;107:322s-331s.
170. Lien HH, Lindskold L, Fossa SD, Aass N. Computed tomography and conventional radiography in intrathoracic métastases from non-seminomatous testicular tumor. Acta Radiol 1988:29:547-9.
171. Chang AE, Schange EG, Conkle DM, Flye MW, Doppman JL, Rosenberg SA. Evaluation of computed tomography in the detection of pulmonary métastases: a prospective study. Cancer 1979:43:913-6.
172. Dinkel E, Mundinger A, Schopp D, Grosser G, Hauenstein KH. Diagnostic imaging in metastatic lung disease. Lung 1990; 168:1129s-1136s.
173. Blickman JG, Aarts JC, Oudkerk M, Simon M. Reconsideration of conventional tomography versus computerized tomography in the evaluation of lung métastases. EurJ Radiol 1986:6:259-61.
174. Feuerstein IM, Jicha DL, Pass HI, et al. Pulmonary métastases: MR imaging with surgical correlation: a prospective study. Radiology 1992; 182:123-9.
175. Pass HI, Dwyer A, Makuch R, Roth JA. Detection of pulmonary métastases in pa-tients with osteogenic and soft-tissue sarcomas: the superiority of CT scans compared with conventional linear tomograms using dynamic analysis. J Clin Oncol 1985:3:1261-5.
176. Takita H, Merrin C, Didolkar MS, Douglass HO, Edgerton BS. The surgical management of multiple lung métastases. Ann Thorac Surg 1992;24:359-64.
177. Morrow CE, Vassilopoulos PP, Grange TB. Surgical resection for metastatic neoplasms of the lung: experience at the University of Minnesota Hospitals. Cancer 1980;45:2981-5.
178. McCormack PM, Martini N. The changing role of surgery for pulmonary métastases. Ann Thorac Surg 1979;28:139-45.
179. Mountain CF, McMurtrey MJ, Hermes KE. Surgery for pulmonary metastsis: a 20-year experience. Ann Thorac Surg 1984;38:323-30.
180. Johnston MR. Median sternotomy for resection of pulmonary métastases. J Thorac Cardiovasc Surg 1983;85:516-22.
181. Roth JA, Pass HI, Wesley MN, White D, Putnam JB, Seipp C. Comparison of median sternotomy and thoracotomy for resection of pulmonary métastases in patients with adult soft-tissue sarcomas. Ann Thorac Surg 1986;42:134-8.
182. Bains MS, Ginsberg RJ, Jones WG, et al. The clamshell incision: an improved approach to bilateral pulmonary and mediastinal tumor. Ann Thorac Surg 1994;58:30-3.
183. Putnam JBJ, Roth JA, Wesley MN, Johnston MR, Rosenberg SA. Analysis of prognostic factors in patients undergoing resection of pulmonary métastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 1984;87:260-7.
184. Udelsman R, Roth JA, Lees D, Jelenich SE, Pass HI. Endobronchial métastases from soft tissue sarcoma. J Surg Oncol 1986;32:145-9.
185. Jablons D, Steinberg SM, Roth JA, Pittaluga S, Rosenberg SA, Pass HI. Metastasectomy for soft tissue sarcoma: further evidence for efficacy and prognostic indicators. J Thorac Cardiovasc Surg 1989;97:695-705.
186. Mineo TC, Cristino B, Ambrogi V, Natali GL, Casciani CU. Usefulness of the Nd: YAG laser in parenchyma-sparing resection of pulmonary nodular lesions. Tumori 1994;80:365-9.
187. Dowling RD, Keenan RJ, Person PF, Landreneau RJ. Video-assisted thoracoscopic resection of pulmonary métastases. Ann Thorac Surg 1993;56:772-5.
188. Harvey JC, Lee K, Beattie EJ. Utility of the neodymium: yttrium-aluminum-garnet (Nd: YAG) laser for extensive pulmonary metastasectomy. J Surg Oncol 1993 ;54:175-9.
189. Branscheid D, Krysa S, Wollkopf G, et al. Does ND-YAG laser extend the indications for resection of pulmonary métastases. Eur J Cardiothorac Surg 1992;6:590-6.
190. Kodama K, Doi O, Higashiyama M, Tatsuta M, Iwanaga T. Surgical management of lung métastases: usefulness of resection with the neodymium: yttrium-aluminum-garnet laser with median sternotomy. J Thorac Cardiovasc Surg 1991;101:901-8.
191. Miyamoto H, Masaoka T, Hayakawa K, Hâta E. Application of the Nd-YAG laser for surgical resection of pulmonary métastases. Kyobu Geka 1992;45:56-9.
192. Landreneau RJ, Haxelrigg SR, Johnson JA, Boley TM, Nawarawong W, Curds JJ. Neodymium:yttrium-aluminum garnet laser-assisted pulmonary resections. Ann Thorac Surgi 991 ;51:973-8.
193. Liu HP, Lin PJ, Hsieh MJ, Chang JP, Chang CH. Application of thoracoscopy for lung métastases. Chest 1995;107:266-8.
194. Miller DL, Alien MS, Trastek VF, Deschamps C, Pairolero PC. Videothoracoscopic wedge excision of the lung. Ann Thorac Surg 1992;54:410-3.
195. Landreneau RJ, Hazelrigg SR, Person PF, et al. Thoracoscopic resection of 85 pulmonary lesions. Ann Thorac Surg 1992;54:415-20.
196. Walsh GL, Nesbitt JC. Tumor implants following thoracoscopic resection of a metastatic sarcoma. Ann Thorac Surg 1995;59:215-6.
197. Johnston MR, Minchen RF, Dawson CA. Lung perfusion with chemotherapy in pa-tients with unresectable metastatic sarcoma to the lung or diffuse bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg 1995;110:368-73.
198. Ng B, Lenert JT, Weksler B, Port JL, Ellis JL, Burt ME. Isolated lung perfusion with FUDR is an effective treatment for colorectal adenocarcinoma lung métastases in rats. Ann Thorac Surg 1995;59:205-8.
199. Ratio GB, Esposito M, Leprini A, et al. In situ lung perfusion with cisplatin: an experimental study. Cancer 1993:71:2962-70.
200. Weksler B, Ng B, Lenert JT, Burt ME. Isolated single-lung perfusion: a study of the optimal perfusate and other pharmacokinetic factors. Ann Thorac Surg 1995; 60:624-9.
201. Pass HI, Mew DJY, Kranda K, Temeck B, Donington J, Rosenberg SA. Isolated lung perfusion with tumor necrosis factor for pulmonary métastases [Discussion]. Ann Thorac Surg 1996:61:1617.
202. Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP. Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long term survival. Cancer 1995:75:1084-93.
203. Goorin AM, Shuster JJ, Baker A, Horowitz ME, Meyer WH, Link MP. Changing pattern of pulmonary métastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol 1991:9:600-5.
204. Al Jilaihawi AN, Bullimore J, Mott M, Wisheart JD. Combined chemotherapy and surgery for pulmonary métastases from osteogenic sarcoma: results of 10 years experience. Eur J Cardiothorac Surg 1988;2:37-42.
205. Huth JF, Eilber FR. Patterns of recurrence after resection of osteosarcoma of the extremity. Arch Surg 1989; 124:122-6.
206. Meyer WH, Schell MJ, Jumar PM, Rao BN. Thoracotomy for pulmonary metastatic osteosarcoma: an analysis of prognostic indicators of survival. Cancer 1987:59:374-9.
207. Snyder CL, Saltzman DA, Ferrell KL, Thompson RC, Leonard AS. A new aporoach to the resection of pulmonary osteosarcoma métastases: results of aggressive metastasectomy. Clin Orthop 1991;270:247-53.
208. Belli L, Scholl S, Livartowski A. Resection of pulmonary métastases in osteosarcoma: a retrospective analysis of 44 patients. Cancer 1989;63:2546-50.
209. Carter SR, Grimer RJ, Sneath RS, Matthews HR. Results of thoracotomy in osteogenic sarcoma with pulmonary métastases. Thorax 1991;46:727-31.
210. Jaffe N, Smith E, Abelson HT, Frei E. Osteogenic sarcoma: alterations in the pattern of pulmonary métastases with adjuvant chemotherapy. J Clin Oncol 1983;1:251-4.
211. Putnam JBJ, Roth JA, Wesley MN, Johnston MR, Rosenberg SA. Survival following aggressive resection of pulmonary métastases from osteogenic sarcoma: analysis of prognostic factors. Ann Thorac Surg 1983;38:516-23.
212. Rosen G, Huvos AG, Mosende C, et al. Chemotherapy and thoracotomy for metastatic osteogenic sarcoma. A model for adjuvant chemotherapy and the rationale for the timing of thoracic surgery. Cancer 1978;41:841-9.
213. Potter DA, Glenn J, KinsellaT, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol 1985;3:353-66.
214. Casson AG, Putnam JB, Natarajan G, et al. Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer 1991:69:662-8.
215. Van Geel AN, Van Coevorden F, Blankensteijn JD, et al. Surgical treatment of pulmonary métastases from soft tissue sarcomas: a retrospective study in the netherlands. Surg Oncol 1994;56:172-7.
216. Rizzoni WE, Pass HI, Wesley MN, Rosenberg SA, Roth JA. Resection of recurrent pulmonary métastases in patients with adult soft tissue sarcomas. Arch Surg 1986;121:1248-52.
217. Pogrebniak HW, Roth JA, Steinberg SM, Rosenberg SA, Pass HI. Reoperative pulmo-nary resection in patients with metastatic soft tissue sarcoma. Ann Thorac Surg 1991:52:197-203.
218. Casson AG, Putnam JB, Natarajan G, et al. Efficacy of pulmonary metastasectomy for recurrent soft tissue sarcoma. J Surg Oncol 1991 ;47:1-4.
219. Weh HJ. Zügel M, Wingberg D, et al. Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. Onkologie 1990:13:448-52.
220. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic orunresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989:7:1208-16.
221. Murray KD. Excision of pulmonary metastasis of colorectal cancer. Semin Surg Oncol 1991:7:157-61.
222. Blister SJ, DeVarennes B, Gordon PH, Sheiner NM, Pym J. Contemporary operative management of pulmonary métastases of colorectal origin. Dis Colon Rectum 1988:31:786-92.
223. Roberts DG, Lepore V, Cardillo G, et al. Long-term follow-up of operative treatment for pulmonary métastases. Eur J Cardiothorac Surg 1989;3:292-6.
224. Scheele J, Altendorf H, Stangl R, Gall FP. Pulmonary resection for metastatic colon and upper rectum cancer: is it useful. Dis Colon Rectum 1990;33:745-52.
225. Goya T. Miyazawa N, Kondo H, Tsuchiya R, Naruke T, Suemasu K. Surgical resection of pulmonary métastases from colorectal cancer: 10-year follow-up. Cancer 1989:64:1418-21.
226. Mansel KJ, Zinsmeister AR, Pairolero PC, Jett JR. Pulmonary resection of metatastic colorectal adenocarcinoma. Chest 1986:1:109-12.
227. Gough DB, Donohue JH, Trastek VA, Nagorney DM. Resection of hepatic and pulmonary métastases in patients with colorectal cancer. Br J Surg 1994;81:94-6.
228. Sauter ER, Bolton JS, Willis GW, Farr GH, Sardi A. Improved survival after pulmonary resection of metastatic colorectal carcinoma. J Surg Oncol 1990;43:135-8.
229. McAfee MK, Alien MS, Trastek VF, Ilstrup DM, Deschamps C, Pairolero PC. Colorectal lung métastases: results of surgical excision. Ann Thorac Surg 1992:53:780-6.
230. Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South MedJ 1988:81:1109-12.
231. Lanza LA, Natarajan G, Roth JA, Putnam JB Jr. Long term survival following resection of pulmonary métastases from carcinoma of the breast. Ann Thorac Surg 1992:54:244-8.
232. Staren ED, Salerno C, Rongione A, WittTR, Faber LP. Pulmonary resection for metastatic breast cancer. Arch Surg 1992:127:1282-4.
233. McDonald ML, Deschamps C, Illstrup DM, Alien MS, Trastek VF, Pairolero PC. Pulmonary resection for metastatic breast cancer. Ann Thorac Surg 1994;58:1599-602.
234. Tesoro-Tess JD, Pizzocaro G, Zanoni F, et al. Reliability of diagnostic imaging after orchiectomy alone in follow-up of clinical stage I testicular carcinoma: excessive cost with potential risk. Lymphology 1987:20:161-5.
235. Williams MP, Husband JE, Heron CW. Intrathoracic manifestations of metastatic testicular seminoma: a comparison of chest radiographie and CT findings. Am J Roentgenol 1987:149:473-5.
236. Kulkarni RP, Reynolds KW, Newland ES, et al. Cytoreductive surgery in disseminated non-seminomatous germ cell tumours of testis. Br J Surg 1991:78:226-9.
237. Van Schil P, Vaneerdeweg W, Schoofs E, Van Oosterom A, Bourgeois N. Surgical excision of pulmonary métastases from primary testicular cancer: case reports. Acta ChirBelg 1989;89:175-8.
238. Carsky S, Ondrus D, Schnorrer M, Majek M. Germ cell testicular tumours with lung métastases: chemotherapy and surgical treatment. Int Urol Nephrol 1992:24:305-11.
239. Carter GE, Lieskovsky G, Skinner DG, Daniels JR. Reassessment of the role of adjunctive surgical therapy in the treatment of advanced germ cell tumors. J Urol 1987;138:1397-401.
240. Anyanwu E, Krysa S, Buelzebruck H, Vogt-Moykopf I. Pulmonary metastasectomy as secondary treatment for testicular tumors. Ann Thorac Surg 1994;57:1222-8.
241. Fuller AF, Scannell JG, Wilkins EW. Pulmonary resection for métastases from gynecologic cancers: Massachusetts general hospital experience 1943-1982. Gynecol Oncol 1985;22:174-80.
242. Levenback C, Rubin SC, McCormack PM, Hoskins WJ, Atkinson EN, Lewis JL Jr. Resection of pulmonary métastases from uterine sarcomas. Gynecol Oncol 1992:45:202-5.
243. 239a. Kumar J, IlancheranA, Ratnam SS. Pulmonary métastases in gestational trophoblastic disease: a review of 97 cases. Br J Obstet Gynaecol 1988;95:70-4.
244. Jones WB, Romain K, Erlandson RA, Burt ME, Lewis JL Jr. Thoracotomy in the management of gestational choriocarcinoma: a clinicopathologic study. Cancer 1993:72:2175-81.
245. Barter JF, Soong SJ, Hatch KD, Orr JW, Shingleton HM. Diagnosis and treatment of pulmonary métastases from cervical carcinoma. Gynecol Oncol 1990:38:347-51.
246. Imachi M, Tsukamoto N, MatsuyamaT, Nakano H. Pulmonary metastasis from carcinoma of the uterine cervix. Gynecol Oncol 1989:33:189-92.
247. Seki M, Nakagawa K, Tsuchiya S, et al. Surgical treatment of pulmonary métastases from uterine cervical cancer: operation method by lung tumor size. J Thorac Cardiovasc Surg 1992:104:876-81.
248. Dernevik H, Berggren H, Larsson S, Roberts D. Surgical removal of pulmonary métastases from renal cell carcinoma. Scand J Urol Nephrol 1985; 19:133-7.
249. Pogrebniak HW, Haas G, Linehan WM, Rosenberg SA, Pass HI. Renal cell carcinoma: resection of solitary and multiple métastases. Ann Thorac Surg 1992;54:33-8.
250. de Forges A, Rey A, Klink M, Ghosn M, Kramar A, Droz JP. Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Semin Surg Oncol 1988:4:149-54.
251. Pogrebniak HW, Stovroff M, Roth JA, Pass HI. Resection of pulmonary métastases from malignant melanoma: results of a 16-year experience. Ann Thorac Surg 1988;46:20-3.
252. Gorenstein LA, Putnam JB Jr, Natarajan G, Balch CA, Roth JA. Improved survival after resection of pulmonary métastases from malignant melanoma. Ann Thorac Surg 1991;52:204-10.
253. Harpole DH Jr, Johnson CM, Wolfe WG, George SL, Seigier HF. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 1992;103:743-50.
254. Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc 1995:110:119-29.
255. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for Tl NO non-small cell lung cancer. Lung cancer study group. Ann Thorac Surg 1995:60:615-22.
256. Finley RJ III, Verazin GT, Driscoll DL, et al. Results of surgical resection of pulmonary métastases of squamous cell carcinoma of the head and neck. Am J Surg 1992:164:594-8.
257. Mazer TM, Robbins KT, McMurtrey MJ, Byers RM. Resection of pulmonary métastases from squamous carcinoma of the head and neck. Am J Surg 1988; 156:238-42.
258. Lefor AT, Bredenberg CE, Kellman RM, Aust JC. Multiple malignancies of the lung and head and neck: second primary tumor or metastasis. Arch Surg 1986; 121:265-70.
259. La Quaglia MP. The surgical management of métastases in pédiatrie cancer (review). Semin Pediatr Surg 1993:2:75-82.
260. Macklis RM, Oltikar A, Sallan SE. Wilms' tumor patients with pulmonary métastases. Int J Radiât Oncol Biol Phys 1991;21:1187-93.
261. Wilimas JA, Douglass EC, Magill HL, Fitch S, Hustu HO. Significance of pulmonary computed tomography at diagnosis in Wilms' tumor. J Clin Oncol 1988;6:1144-6.
262. de Kraker J, Lemerle J, Voute PA, Zucker JM, Tournade MF, Carli M. Wilms' tumor with pulmonary métastases at diagnosis: the significance of primary chemotherapy. J Clin Oncol 1990;8:1187-90.
263. Di Lorenzo M, Collin PP. Pulmonary métastases in children: results of surgical treatment. J Pediatr Surg 1988;23:762-5.
264. Green DM, Breslow NE, Li Y, et al. The role of surgical excision in the management of relapsed Wilms' tumor patients with pulmonary métastases: a report from the National Wilms' Tumor Study. J Pediatr Surg 1991;26:728-33.
265. Lanza LA, Miser JS, Pass HI, Roth JA. The role of resection in the treatment of pulmonary métastases from Ewing's sarcoma. JThorac Cardiovasc Surg 1987;94:181-7.
266. Beattie EJ, Harvey JC, Marcove R, Martini N. Results of multiple pulmonary resections for metastatic osteogenic sarcoma after two decades. J Surg Oncol 1991 ;46:154-5.
267. Pastorino U, Gasparini M, Tavecchio L, et al. The contribution of salvage surgery to the management of childhood osteosarcoma. J Clin Oncol 1991 ;9:1357-62.
268. Yamaguchi H, Nojima T, Yagi T, et al. The alterations in the pattern of pulmonary metastasis with adjuvant chemotherapy in osteosarcoma. Int Orthop 1988;12:305-8.
269. Burgers JMV, Van Glabbeke M, Busson A, et al. Osteosarcoma of the limbs: report of the EORTC-SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation. Cancer 1988;61:1024-31.
270. Zaharia M, Caceres E, Valdivia S, Moran M, Tejada F. Postoperative whole lung irradiation with or without adriamycin in osteogenic sarcoma. Int J Radiât Oncol Biol Phys 1986;12:907-10.
271. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am StatAssocJ 1958:53:457-81.
272. Gehan EA. A generalized wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965;52:203-23.
273. Thomas DG. Exact and asymptotic methods for the combination of 2 times 2 tables. Comput Biomed Res 1975;8:423-46.
274. Cox DR. Regression models and life-tables. J R Stat Soc Series B 1972;34:187-220.
275. Schlappack OK, Baur M, Steger G, Dittrich C. The clinical course of lung métastases from breast cancer. Klin Wochenschr 1988;66:790-5.
276. Pastorino U, Valente M, Gasparini M, Azzarelli A. Lung resection as salvage treatment for metastastic osteosarcoma. Tumori 1988;74:201-6.
277. Roth JA, Putnam JBJ, Wesley MN, Rosenberg SA. Deferring determinants of prognosis following resection of pulmonary métastases from osteogenic and soft tissue sarcoma patients. Cancer 1985:55:1361-6.
278. Jett JR, Hollinger CG, Zinsmeister AR, Pairolero PC. Pulmonary resection of metastatic renal cell carcinoma. Chest 1983;84:442-5.
279. Collins VP, Loeffler RK, Tivey H. Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 1956:76:988-1000.
280. Joseph WL, Morton DL, Adkins RC. Prognostic significance of tumor doubling time in evaluating operability in pulmonary metastatic disease. J Thorac Cardiovasc Surg 1971:61:23-32.
281. Joseph WL, Morton DL, Adkins PC. Variation in tumor doubling time in patients with pulmonary metastatic disease. J Surg Oncol 1971:3:143-9.
282. Rooser B, Pettersson H, Alvegard T. Growth rate of pulmonary métastases from soft tissue sarcoma. Acta Oncol 1987;26:189-92.
283. Creagan ET, Fleming TR, Edmonson JH, Pairolero PC. Pulmonary resection for metastatic non-osteogenic sarcoma. Cancer 1979:44:1908-12.
284. Gottlieb JA, Baker LH, Quagliana JM, et al. Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 1972;30:1632-8.
285. Omura G, Major F, Blessing J, et al. A randomized study of adriamycin with and without DTIC in advanced uterine sarcomas. Cancer 1983;52:626-32.
286. Lerner H, Amato D, Stevens C, Borden E, Enterline H. Leiomyosarcoma: the eastern cooperative oncology group experience with 222 patients. Proceedings of the American Association for Cancer Research 1983;24:142.
287. Benjamin R, Gottlieb J, Baker L. CYVADIC VS. CYVADACT: a randomized trial of cyclophosphamide, vincristine and adriamycin plus either dacarbazine or actinomycin D in metastatic sarcomas. Proceedings of the American Association of Cancer Research 1976;17:256-6.
288. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987;5:840-50.
289. Schoenfeld DA, Rosenbaum C, Horton J, Wolter JM, Falkson G, DeConti RC. A comparison of adriamycin vs. vincristine and adriamycin and cyclophosphamide vs. vincristine actinomycin D and cyclophosphamide for advanced sarcoma. Cancer 1982;50:2757-62.
290. Pinedo HM, Bramwell VHC, Mouridson HT, et al. Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC soft tissue and bone sarcoma group. Cancer 1984;53:1825-32.
291. Bodey GP, Rodriquez V, Murphy WK, Burgess MA, Benjamin RS. Protected environment-prophylactic antibiotic program for malignant sarcomas: randomized trial during remission induction chemotherapy. Cancer 1981 ;47:2422-9.
292. Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a southwest oncology group study. J Natl Cancer Inst 1991;83:926-32.
293. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to Ifosfamide and MESNA: 124 previously treated patients with metastatic unresectable sarcoma. J Clin Oncol 1989;7:126-31.
294. Scheulen ME, Niederle N, Bremer K, Schotte J, Seeber S. Efficacy of ifosfamide and refractory malignant diseases and uroprotection by MESNA: results of a clinical phase II-study with 151 patients. Cancer Treat Rev 1983;10:93s-101s.
295. Klein HO, Wickramanayake PD, Coerper CL, Christian E, Pohl J, Brock N. High dose ifosfamide and MESNA as continuous infusion over 5 days-a phase I/II trial. Cancer Treat Rev 1983;10:167s-173s.
296. Schutte J, Mouridsen HT, Stewart W, et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. Eur J Cancer 1990:26:558-61.
297. Loehrer PJ Sr, Sledge GW Jr, Nicaise C, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J Clin Oncol 1989:7:1655-9.
298. Elias A, Ryan L, Aisner J, Antman KH. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol 1990;17:4 ls-49s.
299. Steward WP, Verweij J, Somers R, et al. Doxorubicin plus ifosfamide with rh GM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC soft-tissue and bone sarcoma group. J Cancer Res Clin Oncol 1991;117:193s-197s.
300. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75.
301. Antman KH, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-85.
302. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin vs. cyVADIC vs. doxorubicin plus ifosfamide in first-line treatment of advanced soft-tissue sarcomas: a randomized study of the EORTC soft-tissue and bone sarcoma group. J Clin Oncol 1995;13:1537-45.
303. Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent Ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol 1993;31:174s-179s.
304. Gabrilove JL, Jakubowski A, Sher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of urothelium. N Engl J Med 1988;318:1414-22.
305. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of the fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70.
306. Antman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988;319:593-8.
307. Vadhan-Raj S, Broxmeyer HE, Hittleman WN, et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 1992;10:1266-77.
308. Vadhan-Raj S, Papadopoulos NE, Burgess MA, et al. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol 1994; 12:715-24.
309. Vadhan-Raj S, Broxmeyer HE, Burgess M, et al. Schedule-dependent reduction in CyADIC chemotherapy(ct)-induced multilineage hematopoietic toxicity by PIXY321 in patients with sarcoma. Proceedings of the American Society for clinical Oncology 1994;13:475-5.
310. Cheson BD, Lacerna L, Leyland-Jones B, Sarosy G, Wittes RE. Autologus bone marrow transplantation: current status in future directions. Ann Int Med 1989; 110:51 -65.
311. Antman K, Eder JP, Frei E. High dose chemotherapy with bone marrow support for solid tumors. In: De Vita VT Jr, Hellman S, Rosenberg SA, editors. Important advances in advanced oncology 1987. Philadelphia: J.B. LippincottCo., 1987:221-35.
312. Korbling M, Juttner CH, Henon PH, Kessinger A. Autologous blood stem cells versus bone marrow transplantation. Bone Marrow Transplant 1992;10:144s-148s.
313. Weksler B, Ng B, Lenert J, Burt ME. Isolated single-lung perfusion with doxorubicin is pharmacokinetically superior to intravenous injection. Ann Thorac Surg 1993;56:209-14.
314. Weksler B, Lenert J, Ng B, Burt M. Isolated single lung perfusion with doxorubicin is effective in eradicating soft tissue sarcoma lung métastases in a rat model. J Thorac Cardiovac Surg 1994;107:50-4.
315. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer 1993;72:3244-7.
316. Weiss AJ, Lackman RD. Low-dose chemotherapy of desmoid tumors. Cancer 1989;64:1192-4.
317. Brooks MD, Ebbs SR, Colletta AA, Baum M. Desmoid tumors treated with triphenylethylenes. Eur J Cancer 1992;28A: 1014-8.
318. Kinzbrunner B, Ritter S, Domingo J, Rosenthal CJ. Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer 1983;52:2201-4.
319. Lanari A. Effect of progesterone in desmoid tumors (aggressive fibromatosis). N Engl JMed 1983;309:1523-3.
320. Patel SR, Plager C, Papadopoulos N, et al. Myxoid malignant fibrous histiocytoma: experience with chemotherapy. Am J Clin Oncol 1995;18:161-3.
321. Patel SR, Burgess MA, Plager C, Papadopoulos NE, Linke KA, Benjamin RS. Myxoid liposarcoma: experience with chemotherapy. Cancer 1994;74:1265-9.
322. Patel SR, Burgess MA, Papadopoulos N, Linke K, Benjamin RS. Extraskeletal myxoid chondrosarcoma: long-term experience with chemotherapy. Am J Clin Oncol 1995:18:161-3.
323. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable métastases at initial presentation. J Clin Oncol 1993;11:449-53.
324. Ward WG, Mikaelian K, Dorey F, et al. Pulmonary métastases of stage IIB extremity osteosarcoma and subsequent pulmonary métastases. J Clin Oncol 1994; 12:1849-58.
325. Patel SR, Armen T, Carrasco CH, et al. Primary chemotherapy (CT) in MFH of bone: updated U.T.M.D. Anderson Cancer Center experience. Fourth International Congress on Anti-Cancer Chemotherapy 1993;111.
326. Cangir A, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis: results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990;66:887-93.
327. Grier H, Krailo M, Link M, et al. Improved outcome in non-metastatic ewing's sarcoma (ews) and PNET of bone with the addition of ifosfamide(i) and etoposide(e) to vincristine(v), adriamycin(ad), cyclophosphamide(c), andactinomycin(a): achildrens cancer group(ccg) and pédiatrie oncology group(pog) report. Program Proceedings of the American Society of Clinical Oncology 1994;13:421.
328. Benjamin RS, Tu P, Patel SR, et al. Dedifferentiated chondrosarcoma: a treatable disease. Proceedings of the American Association for Cancer Research 1995;36:243.
329. Salem P, Benjamin RS, Howard J, et al. Phase II trial of recombinant Interferon alpha-2-b in the treatment of advanced metastatic and refractory sarcomas. Proceedings of the American Association for Cancer Research 1991 ;33:200.
330. Plager C, Howard J, Papadopoulos NEJ, et al. A phase II study of 5-FU infusion, and interferon alpha in metastatic sarcomas. Proceedings of the American Association for Cancer Research 1992;33:229.